Pediatrix (NYSE: MD) director receives 7,196 restricted shares in equity award

Rhea-AI Filing Summary

SANSONE GUY P reported acquisition or exercise transactions in this Form 4 filing.

Pediatrix Medical Group director Guy P. Sansone received a grant of 7,196 shares of restricted common stock as an annual equity award. The shares were granted at no cash cost under the company’s Amended and Restated 2008 Incentive Compensation Plan and will vest on May 7, 2027. Following this award, Sansone directly holds 86,944 shares of Pediatrix Medical Group common stock, reflecting routine stock-based compensation rather than an open-market purchase or sale.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider SANSONE GUY P

Role null

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	7,196	$0.00	--

Holdings After Transaction: Common Stock — 86,944 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Restricted shares granted: 7,196 shares Total shares after transaction: 86,944 shares Grant price per share: $0.0000 per share +1 more

4 metrics

Restricted shares granted 7,196 shares Annual equity award, Common Stock

Total shares after transaction 86,944 shares Direct holdings following award

Grant price per share $0.0000 per share Non-cash restricted stock grant

Vesting date May 7, 2027 Restricted shares vesting schedule

Key Terms

Restricted shares, Amended and Restated 2008 Incentive Compensation Plan, annual equity award, transaction code A

4 terms

Restricted shares financial

"Restricted shares granted pursuant to Issuer's Amended and Restated 2008 Incentive Compensation Plan"

Restricted shares are company stock that cannot be sold or transferred immediately because they are subject to legal or contractual limits, such as a required holding period or performance conditions. They matter to investors because these locked-up shares can affect a company’s available stock for trading, future dilution, and insider incentives—imagine a gift that can’t be cashed until certain conditions are met, which changes when and how much supply can suddenly enter the market.

Amended and Restated 2008 Incentive Compensation Plan financial

"Restricted shares granted pursuant to Issuer's Amended and Restated 2008 Incentive Compensation Plan"

annual equity award financial

"in connection with annual equity award. Shares will vest on May 7, 2027."

transaction code A regulatory

"transaction_code_description: Grant, award, or other acquisition"

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

SANSONE GUY P

(Last) (First) (Middle)

1301 CONCORD TERRACE

(Street)

SUNRISE FLORIDA 33323

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Pediatrix Medical Group, Inc. [ MD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/07/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/07/2026		A(1)		7,196	A	$0	86,944	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Restricted shares granted pursuant to Issuer's Amended and Restated 2008 Incentive Compensation Plan, in connection with annual equity award. Shares will vest on May 7, 2027.

Remarks:

See Exhibit 24.1 - Power of Attorney

	Mary Ann E. Moore, Attorney-in-Fact	05/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Pediatrix Medical Group (MD) director Guy P. Sansone report on this Form 4?

Guy P. Sansone reported receiving 7,196 restricted shares of Pediatrix Medical Group common stock as an annual equity award. The grant was made at no cash cost under the company’s Amended and Restated 2008 Incentive Compensation Plan.

When do Guy P. Sansone’s newly granted restricted Pediatrix (MD) shares vest?

The 7,196 restricted shares granted to Guy P. Sansone will vest on May 7, 2027. Vesting means the shares become fully owned and no longer subject to forfeiture under the terms of the company’s incentive compensation plan.

How many Pediatrix Medical Group (MD) shares does Guy P. Sansone hold after this award?

After the restricted stock grant, Guy P. Sansone directly holds 86,944 shares of Pediatrix Medical Group common stock. This total reflects his updated ownership position as reported in the Form 4 filing with the SEC.

Was Guy P. Sansone’s Pediatrix (MD) Form 4 transaction an open-market buy or sell?

The transaction was not an open-market buy or sell. It was a grant of 7,196 restricted shares as an annual equity award, recorded with transaction code A for grant or award, at a price of $0.0000 per share.

Under which plan were the restricted Pediatrix (MD) shares granted to Guy P. Sansone?

The restricted shares were granted under Pediatrix Medical Group’s Amended and Restated 2008 Incentive Compensation Plan. This plan provides equity-based compensation, such as restricted stock, to directors and other eligible participants as part of their overall compensation.